These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12579085)

  • 21. A strategy to deter blood doping in sport.
    Ashenden MJ
    Haematologica; 2002 Mar; 87(3):225-32. PubMed ID: 11869930
    [No Abstract]   [Full Text] [Related]  

  • 22. [Gene doping: gene transfer and possible molecular detection].
    Argüelles CF; Hernández-Zamora E
    Gac Med Mex; 2007; 143(2):169-72. PubMed ID: 17585706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiological effects of perfluorocarbon blood substitutes.
    Lowe KC; Bollands AD
    Med Lab Sci; 1985 Oct; 42(4):367-75. PubMed ID: 3908874
    [No Abstract]   [Full Text] [Related]  

  • 24. Allosteric modification of oxygen delivery by hemoglobin.
    Wahr JA; Gerber M; Venitz J; Baliga N
    Anesth Analg; 2001 Mar; 92(3):615-20. PubMed ID: 11226087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxygen therapeutics: perfluorocarbons and blood substitute safety.
    Cohn CS; Cushing MM
    Crit Care Clin; 2009 Apr; 25(2):399-414, Table of Contents. PubMed ID: 19341916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravenous perfluorocarbons. Artificial oxygen carriers and their medical applications].
    Frietsch T; Lenz C; Waschke KF
    Dtsch Med Wochenschr; 2000 Apr; 125(15):465-72. PubMed ID: 10800445
    [No Abstract]   [Full Text] [Related]  

  • 27. [Fluorocarbon emulsions--artificial blood?].
    Frick G; Frick U
    Zentralbl Chir; 1982; 107(18):1137-41. PubMed ID: 7180230
    [No Abstract]   [Full Text] [Related]  

  • 28. Points to consider on efficacy evaluation of hemoglobin- and perfluorocarbon-based oxygen carriers. Center for Biologics Evaluation and Research.
    Transfusion; 1994 Aug; 34(8):712-3. PubMed ID: 8073490
    [No Abstract]   [Full Text] [Related]  

  • 29. [Point of view on doping].
    Naeije R; Pagnamenta A
    Rev Med Brux; 1999 Jun; 20(3):153-8. PubMed ID: 10429539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection methods for autologous blood doping.
    Segura J; Monfort N; Ventura R
    Drug Test Anal; 2012 Nov; 4(11):876-81. PubMed ID: 22407819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Doping and sports].
    Lippi G; Guidi G
    Minerva Med; 1999 Sep; 90(9):345-57. PubMed ID: 10719440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. World anti-doping regulations for 2005: essential changes for athletes and physicians.
    Pabinger C; Gruber G
    Arch Orthop Trauma Surg; 2006 May; 126(4):286-8. PubMed ID: 16333634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
    Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M
    J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene doping.
    Haisma HJ; de Hon O
    Int J Sports Med; 2006 Apr; 27(4):257-66. PubMed ID: 16572366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry.
    Breidbach A; Catlin DH
    Rapid Commun Mass Spectrom; 2001; 15(24):2379-82. PubMed ID: 11746905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The heart and doping].
    Gauthier J
    Arch Mal Coeur Vaiss; 2006 Nov; 99(11):1126-9. PubMed ID: 17181045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial oxygen tension during fatal right heart failure following perfluorocarbon and radiographic contrast agent interaction.
    Matschke K; Franke RP; Mrowietz C; Gerk U; Klosterhalfen B; Knaut M; Jung F
    Clin Hemorheol Microcirc; 2005; 33(1):57-62. PubMed ID: 16037633
    [No Abstract]   [Full Text] [Related]  

  • 39. Hormone abuse in sports: the antidoping perspective.
    Barroso O; Mazzoni I; Rabin O
    Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxygen carriers ("blood substitutes").
    Topfer LA; Hailey D
    Issues Emerg Health Technol; 2001 Jul; (21):1-6. PubMed ID: 11776287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.